Moderna has announced that the FDA will initiate the review of its seasonal influenza vaccine candidate, mRNA-1010.

Novo Nordisk is running a Phase Ib/IIa trial of the drug in patients who are overweight or with obesity. Image credit: Kittyfly / Shutterstock.com Novo Nordisk and United Laboratories’ jointly ...

The Phase I/IIa study evaluates six-month dosing over 12 months for safety, tolerability, pharmacodynamic and pharmacokinetics effects. Credit: PhotobyTawat / Shutterstock.com. Vico Therapeutics has ...

JAG201 is a one-time gene replacement therapy using an AAV9 vector delivering a functional SHANK3 minigene to neurons. Credit: Antonio Marca / Shutterstock.com. Clinical-stage biotechnology company ...

The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway” ...

Patients with HIV showed lower cases of steatotic liver disease when switched to ViiV Healthcare’s Dovato compared to ...

C4 Therapeutics has dosed the first patient in its Phase II MOMENTUM trial of cemsidomide, an oral IKZF1/3 degrader, combined with dexamethasone for patients with RRMM.

Gossamer Bio has reported topline data from the Phase III PROSERA study evaluating seralutinib in patients with PAH.

In the trial, CagriSema appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema ...

The trial was launched by King’s College London following the UK’s ban of puberty blockers in under 18s. Image credit: Dmitry Demidovich / Shutterstock.com An investigator-led trial that is ...

Around 89% of eligible participants completed the therapy through week 140. Credit: Gorodenkoff / Shutterstock.com. Johnson & Johnson (J&J) has reported new findings from the QUASAR long-term ...

The Phase I trial aims to assess tolerability, activity, and safety of ZI-MA4-1 in patients with advanced cancers. Credit: Inna Dodor / Shutterstock.com. Zelluna has received the UK Medicines and ...